巴西官員：將把中國新冠疫苗納入國家免疫計畫
2020/10/23
當地時間20日，巴西多位州長在與該國衛生部長會晤後宣佈，除了製藥巨頭阿斯利康公司和英國牛津大學研製的疫苗外，巴西政府還將把中國科興生物技術公司開發的新冠病毒疫苗CoronaVac納入國家免疫計畫。
聖保羅州州長若昂·多利亞表示，巴西聯邦政府已經同意購買4600萬劑中國製造的新冠病毒疫苗。他還稱，巴西免疫接種計畫最早將於2021年1月啟動。
巴西聖保羅州布坦坦研究所19日表示，對9000名志願者進行臨床試驗的初步結果證明，中國的疫苗是安全的，有關疫苗有效性的資料要等試驗完成後才能公佈。
The Brazilian government will include China’s Sinovac vaccine against COVID-19 in its national immunization program, state governors said on Tuesday after a meeting with the country’s health minister, in addition to one developed by AstraZeneca and Oxford University.
This means the experimental Chinese vaccine called Coronavac, which Brazil’s largest state of Sao Paulo had hoped to provide to its residents, may also be used to vaccinate Brazilians elsewhere, a major success for Sinovac in a nation of 230 million people.
The federal government already has plans to purchase the UK vaccine and produce it at its biomedical research center FioCruz in Rio de Janeiro, while the Chinese vaccine is being tested by Sao Paulo state’s research center Butantan Institute.
Sao Paulo Governor Joao Doria said after the Health Ministry meeting that the federal government has agreed to buy 46 million doses of the Sinovac vaccine.
The national vaccination program could begin in January 2021, he said, which could make it one of the first immunization efforts against coronavirus in the world.
The Butantan Institute said on Monday that preliminary results from late-stage clinical trials of CoronaVac on 9,000 volunteers have proven that the two-dose Chinese vaccine is safe.
Butantan director Dimas Covas said data on how effective the vaccine is will not be released until the trial is completed.
The result is only preliminary and researchers will keep monitoring the participants in the ongoing trial, Covas said. It’s the first set of results of Sinovac’s global Phase III trials, which are also being conducted in Turkey and Indonesia.
The Sao Paulo government has already asked health regulators to approve CoronaVac for use, a major step in what could be one of the first vaccination programs in the Americas.
Vaccine for all
在20日國務院聯防聯控機制召開的新聞發佈會上，科技部社會發展科技司副司長田保國介紹，目前我國新冠疫苗研發工作總體處於領先地位，已有13個疫苗進入臨床階段。其中，滅活疫苗和腺病毒載體疫苗兩種技術路線共4個疫苗進入三期臨床，總體進展順利。截至目前，共計約6萬名受試者接種，未接到嚴重不良反應報告。
上周，50多位非洲國家駐華使節和高級外交官集體赴國藥集團北京生物製品研究所參觀，聽取國藥集團關於中國疫苗技術、新冠肺炎疫苗研發等情況介紹。
國家衛生健康委科技發展中心主任鄭忠偉此前介紹，預計今年年底我國疫苗的產能能達到6.1億劑。明年，我國新冠疫苗的年產能在此基礎上會有效擴大，切實保證我國以及全球其他國家對中國新冠疫苗的需求。
At a Tuesday press conference, a Chinese official said nearly 60,000 people have been injected with China’s COVID-19 vaccines so far and no one has reported severe adverse reactions.
Among the country’s 13 vaccines in clinical trials, four candidates have entered Phase III trials with volunteers across 10 countries. In addition to Brazil, developing countries in Southeast Asia, and Africa have also undergone various Chinese vaccine experiments.
Last week, a group of ambassadors and diplomats from 50 African countries were invited to visit China’s largest vaccine maker Sinopharm. In the vaccine factory, they were briefed about the Phase III clinical trials of the company’s COVID-19 vaccine, which is being carried out in 10 countries including the United Arab Emirates, Peru and Argentina with more than 50,000 volunteers involved.
The company is the first to build a high-grade bio-safety production facility for the inactivated COVID-19 vaccine. It is estimated that the production capacity of the inactivated COVID-19 vaccine will reach more than 1 billion doses in 2021.
China, at large, is expected to produce up to 610 million doses of COVID-19 vaccines by the end of this year, Zheng Zhongwei, head of China’s coronavirus vaccine development task force, said at an earlier press briefing, adding that the capacity will be further expanded next year to meet the huge demand.
編輯 / 王小明
【巴西華人資訊網】
